

# Health Care Provider Bulletin

LifeLabs Service Updates: March 9, 2026

## Changes to Referred-out Testing – Phase I of III

Dear Healthcare Providers,

We are writing to inform you of an upcoming update to a group of LifeLabs tests that are currently referred out to external laboratories. As part of our ongoing efforts to optimize our referred-out testing network and strengthen alignment with a primary reference laboratory, these tests will be transitioned to Quest Diagnostics. This change applies only to tests that are already referred out and will not affect the majority of testing performed within LifeLabs.

To support a smooth implementation, the transition will occur in three phases between April and July 2026. **Phase I** of this transition will take effect **April 6, 2026**, and includes the following tests:

- Di-Hydrotestosterone (DHT)
- IgG Fractionation Subclasses (test includes: IgG1,IgG2,IgG3,IgG4)

Additional details regarding methodology changes, turnaround times, reference ranges, and specimen handling can be found on page 2 of this communication.

Phase II and Phase III are anticipated for May and July, respectively. Further information will be shared in advance as we approach each implementation date.

This transition will enhance standardization, improve coordination and oversight within our reference laboratory network, streamline test management and quality review processes, and ensure continued access to specialized testing services.

### **Hospital Interface Impact:**

Please note that the Phase 1 LifeLabs tests listed above will require an interface mapping update. If this affects your hospital, please contact Cyndi Kelba ([Cyndi.Kelba@lifelabs.com](mailto:Cyndi.Kelba@lifelabs.com)) for assistance with the required updates.

If you have any questions, please contact LifeLabs Contract Services 1-866-370-5227.

Thank you,  
Contract Services

Phase 1 – Tests Referred-Out to Quest Diagnostics

		Current	New
<b>Dihydrotestosterone</b>	<b>Methodology</b>	Liquid Chromatography Mass Spectrometry (LCMS)	Chromatography/Mass Spectrometry
	<b>TAT</b>	7 days	9 days
	<b>Reference Ranges</b>	Female: 20-55 years ≤1.03 nmol/L >55 years ≤ 0.44 nmol/L  Male: >19 years: 0.39 – 3.29 nmol/L	Female: ≤20 ng/dL  Male: 12-65 ng/dL
	<b>Specimen Handling</b>	Frozen sample collected from SST Tube	Refrigerated sample collected from a red-top tube
<b>IgG Fractionation</b>	<b>Methodology</b>		Immunoturbidimetric Assay
	<b>TAT</b>	10 days	14 days
	<b>Reference Ranges</b>	Please check our Lab Test Information Directory	IgG Subclass1 382-929 mg/dl IgG Subclass2 241-700 mg/dl IgG Subclass3 22-178 mg/dl IgG Subclass4 4-86 mg/dl IgG Serum 600-1640 mg/dl
	<b>Specimen Handling</b>	Frozen serum collected from SST Gold Top Tube	Refrigerated serum collected from SST Gold Top Tube.

## Tests Transitioning in Each Phase

Below are the tests transitioning in each phase. More information will be provided for Phase 2 and 3 as we get closer to their transition dates.

Phase	Test Name	Province
1	IgG fractionation	ON
1	DI-HYDROTESTOSTERONE	ON & BC
2	BETA-2 MICROGLOBULIN(SERUM)	ON
2	BETA-2 MICROGLOBULIN (URINE)	ON
2	PHOSPHOLIPASE A2 RECEPT.	ON
2	VITAMIN B2	ON
3	CHROMOGRANIN A	ON
3	FRUCTOSAMINE	ON
3	COBALT, RANDOM URINE	ON & BC
3	INSULIN ANTIBODIES	ON & BC